Olema Pharmaceuticals OLMA

Sean Bohen, M.D., Ph.D., the Company's Chief Executive Officer, has assumed the role of principal financial officer effective as January 30, 2026. Sean Bohen, M.D., Ph.D. has served as our Chief Executive Officer and as a member of our Board of Directors since September 2020. In August 2019, Dr. Bohen joined AltruBio, Inc. (then AbGenomics, Inc.), a pharmaceutical company, as a member of the board of directors. From September 2015 to April 2019, Dr. Bohen served as the Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca PLC, a pharmaceutical and biopharmaceutical company. From June 2003 to July 2015, he held a number of senior leadership roles at Genentech, Inc., a biotechnology company, including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to that, Dr. Bohen was a Clinical Instructor in Oncology at Stanford University School of Medicine from October 2002 to December 2011, a research associate at the Howard Hughes Medical Institute from July 2000 to June 2003 and a postdoctoral fellow at the National Cancer Institute from January through December 1995. Dr. Bohen received a B.S. in Bacteriology from the University of Wisconsin-Madison, and a Ph.D. in Biochemistry & Biophysics and M.D. from the University of California, San Francisco.

Ms. Shawnte M. Mitchell, J.D. has served as our Chief Legal Officer and Corporate Secretary since February 2025. Prior to joining us, Ms. Mitchell served as Chief Legal Officer at Genomatica, Inc., a biotechnology company, from June 2022 until May 2024. She previously served as Executive Vice President, General Counsel and Corporate Secretary at Zogenix, Inc., a global biopharmaceutical company, from April 2020 until March 2022 (until its acquisition by UCB S.A., a biopharmaceutical company). Before that she was at Aptevo Therapeutics Inc., a clinical-stage biotechnology company, from July 2016 until March 2020, last serving as Senior Vice President of Corporate Affairs, Chief Compliance Officer, and Corporate Secretary. Ms. Mitchell currently serves as a member of the Board of Managers of Life Science Cares Bay Area and is a member of How Women Lead's Silicon Valley Board of Advisors. She received a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School.

Mr. Ian T. Clark has served as a member of our Board of Directors since August 2020. Mr. Clark most recently served as Chief Executive Officer, led the executive committee, and was a member of the board of directors of Genentech, Inc., a biotechnology company, from January 2010 to December 2016. In total, he served for 14 years at Genentech, Inc., of which 12 were on the Genentech, Inc. executive committee, initially as Executive Vice President of Commercial Operations. Before that, Mr. Clark served as Senior Vice President and General Manager of BioOncology. Prior to that, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis International AG, a pharmaceutical company, Sanofi S.A., a healthcare and pharmaceutical company, Ivax Pharmaceuticals, Inc., a pharmaceutical company, and G.D. Searle, LLC (which became a subsidiary of agrochemical company Monsanto Corporation), working in the United Kingdom, Canada, Eastern Europe and France. Mr. Clark has served as a member of the boards of directors of BioMarin Pharmaceutical Inc., a biopharmaceutical company, since August 2025, Kyverna Therapeutics, Inc., a cell therapy company, since September 2021, Corvus Pharmaceuticals, Inc., a biopharmaceutical company, since January 2017, Guardant Health, Inc., a precision oncology company, since January 2017, and Takeda Pharmaceutical Company Limited, a pharmaceutical company, since January 2019 and where he is expected to step down in June 2026. Mr. Clark previously served as a member of the board of directors of GoodRx Holdings, Inc., a prescription savings platform, from July 2024 to March 2026, AVROBIO, Inc., a gene therapy company, from January 2018 to June 2024 (until its acquisition by Tectonic Therapeutics, Inc.), Shire Pharmaceuticals, Inc., a pharmaceutical company, from February 2017 to January 2019 (until its acquisition by Takeda Pharmaceutical Company Limited), Kite Pharma, Inc., a biotechnology company, from January 2017 to October 2017, Forty Seven Inc., an immune-oncology company, from May 2018 to April 2020 and Agios Pharmaceuticals, Inc., a pharmaceutical company, from December 2016 to June 2022. Mr. Clark also?previously served as a member of the board of directors of Gyroscope Therapeutics Holdings PLC, a gene therapy company, TerraVia Holdings, Inc. (formerly Solazyme), a biotechnology company, Dendreon, a biotechnology company, and Vernalis Research, a biotechnology company. Mr. Clark is an advisor to KKR & Co. Inc., a global investment firm, and was previously an advisor at Lazard, a financial services company, Blackstone Life Sciences Inc., an investment management company, and Perella Weinberg Partners LP, a financial services company. He served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. He also served on the BioFulcrum Board of the Gladstone Institute and as Chair of the External Advisory Board to Southampton University's Institute for Life Sciences. Mr. Clark received his B.S. in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.

Ms. Cynthia M. Butitta has served as a member of our Board of Directors since August 2020. Ms. Butitta served as the Chief Operating Officer of Kite Pharma Inc., a biopharmaceutical company, from March 2014 to September 2017 and as its Executive Vice President and Chief Financial Officer from January 2014 to May 2016. From May 2011 to December 2012, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to that, Ms. Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial Officer from August 1998 to December 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She has served as a member of the board of directors of Autolus Therapeutics plc, a cell therapy company, since March 2018 and UroGen Pharma Ltd., a biotechnology company, since October 2017. She also served on the board of directors of Century Therapeutics, Inc., a biotechnology company, from February 2021 to August 2025. Ms. Butitta received a B.S. with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and an M.B.A. in Finance from the University of Wisconsin, Madison.

Ms. Yi Larson has served as a member of our Board of Directors since April 2021. Ms. Larson has served as the President, Chief Executive Officer, and on the board of directors of Expedition Therapeutics Inc., a global biotechnology development company, since April 2024. Ms. Larson served as the Chief Financial Officer of LianBio, a biopharmaceutical company, from May 2021 to December 2023. From August 2019 to March 2021, she was Executive Vice President and Chief Financial Officer of Turning Point Therapeutics, Inc., a precision oncology company. Prior to that, beginning in 2008, Ms. Larson held various roles at Goldman Sachs & Co. LLC, an investment banking securities and investment management company, most recently as Managing Director of Healthcare Investment Banking. During her tenure at Goldman Sachs & Co. LLC, Ms. Larson advised a variety of biopharmaceutical company boards of directors?and management teams on a range of strategic financial matters, and executed equity offerings, debt offerings, and merger and acquisition transactions. She previously served as a member of the board of directors of RayzeBio, Inc., a targeted radiopharmaceuticals company, from April 2021 until its acquisition by Bristol Myers Squibb in February 2024. Ms. Larson graduated from The Wharton School at the University of Pennsylvania with an M.B.A concentrated in Finance. She also earned an M.Eng. in Electrical Engineering and Computer Science and an S.B. in Electrical Engineering, both from the Massachusetts Institute of Technology.

Mr. Andrew S. Rappaport has served as a member of our Board of Directors since January 2013. Mr. Rappaport has served as the Managing Partner at Skyline Public Works, LLC, his family office, since 2003, and as the Managing Partner and Chief Investment Officer of SPW Investments, his family investment vehicle, since 2005. From 1996 to 2014, Mr. Rappaport was a partner at August Capital, a technology venture capital firm. Prior to August Capital, he was the President of the Technology Research Group, a global strategy consulting firm he founded in 1984.

Mr. Scott Garland has served as a member of our Board of Directors since October 2023. Mr. Garland served as the Chief Executive Officer of PACT Pharma, Inc., an immuno-oncology company, from March 2021 to February 2023, and on the board of directors from March 2021 to September 2023. Mr. Garland previously served as President, Chief Executive Officer and a member of the board of directors of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from October 2018 until July 2020 when it was acquired by Alexion Pharmaceuticals, Inc. From April 2017 to September 2018, he served as President of Relypsa Inc., a biopharmaceutical company, and as Senior Vice President and Chief Commercial Officer from October 2014 to April 2017. From October 2011 to October 2014, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc., a biopharmaceutical company. He has served as a member of the board of directors of ALX Oncology, a biotechnology company, since November 2022, Day One Biopharmaceuticals, Inc., a biopharmaceutical company, since August 2021, LB Pharmaceuticals, Inc., a biopharmaceutical company, since March 2024, and Enliven Therapeutics, Inc., a biopharmaceutical company, since January 2026. He previously served on the board of directors of Calithera Biosciences, Inc., a biopharmaceutical company, from July 2020 to December 2023. Mr. Garland has served as an advisor at Vida Ventures, LLC, a venture capital investment firm, since September 2023 and as an advisor to Google Ventures, a venture capital investment firm, since July 2023. Mr. Garland holds a B.S. in Biological Sciences from California Polytechnic State University (San Luis Obispo) and an M.B.A. from Duke University's Fuqua School of Business.

Dr. Sandra J. Horning, M.D. has served as a member of our Board of Directors since November 2020. Dr. Horning served as the Chief Medical Officer and Global Head of Product Development of Roche, Inc., a healthcare company, from January 2014 until her retirement in October 2019, and prior to that as Global Head of Oncology Product Development of Roche, Inc. from September 2009 to December 2013. From July 1980 until August 2009, Dr. Horning was a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, Dr. Horning served as the President of the American Society of Clinical Oncology. Dr. Horning served as a member of the board of directors of Foundation Medicine, Inc., a molecular information company, from April 2015 to July 2018, and EQRx, Inc., a biotechnology company, from August 2020 to November 2023. She has also served as a member of the board of directors of Moderna, Inc., a pharmaceutical and biotechnology company, since March 2020, Gilead Sciences, Inc., a biopharmaceutical company, since January 2020, and Revolution Medicines, Inc., a biotechnology company, since November 2023. Dr. Horning received an M.D. from the University of Iowa School of Medicine and completed her internal medicine training at the University of Rochester and a fellowship in Oncology and Cancer Biology at Stanford University.

Dr. Gorjan Hrustanovic, PhD has served as a member of our Board of Directors since July 2018. Dr. Hrustanovic has served as a Principal at BVF Partners L.P., a biotechnology investment firm, since July 2018 and as an Analyst from September 2015 to July 2018. Dr. Hrustanovic has also served as a member of the board of directors of Kymera Therapeutics, Inc., a biopharmaceutical company, since March 2020 and a number of privately held companies. Dr. Hrustanovic previously served as a member of the board of directors of Rain Oncology, Inc., a biotechnology company, from May 2018 to January 2024. Dr. Hrustanovic received a B.S. in Molecular Biology and a B.S. in Management Science from the University of California, San Diego, and a Ph.D. in Cancer Biology & Cell Signaling from the University of California, San Francisco.

Dr. Graham Walmsley, M.D.,PhD has served as a member of our Board of Directors since March 2020. Dr. Walmsley is a Founding Member and has served as a General Partner of Logos Global Management, LP, a biotechnology-focused investment fund, since August 2019. From July 2016 to August 2019, he served as a Principal at Versant Ventures, a healthcare focused venture capital firm. Dr. Walmsley served as Head of Business Development at Pipeline Therapeutics Inc., a biotechnology company, from April 2018 to December 2018 and as Head of Business Development at Jecure Therapeutics, Inc., a biotechnology company, from June 2017 until its acquisition by Genentech, Inc., a subsidiary of Roche, in November 2018. He also served as a member of the board of directors of Akero Therapeutics, Inc., a biotechnology company, from June 2018 to December 2025 and of ALX Oncology Holdings Inc., an immune-oncology company, from February 2020 until August 2021. Dr. Walmsley received a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a Ph.D. and an M.D. in Stem Cell Biology and Regenerative Medicine from Stanford University School of Medicine.

Dr. Cyrus L. Harmon, PhD has served as a member of our Board of Directors since August 2006. Dr. Harmon has served as the President and Chief Executive Officer of Vilya, Inc., a computational biotechnology company, since October 2023. In addition, he currently serves as manager of Harmon Family Investors, LLC, a family investment office. Dr. Harmon is one of our co-founders, and he served as our President and Chief Executive Officer from March 2007 to September 2020, then as our Chief Technology Officer from September 2020 until July 2022, and then as our Chief Research Officer from July 2022 to March 2023. From 2000 to 2002, Dr. Harmon served as the Vice President of Computational Genomics and General Manager at Affymetrix, Inc., a biotechnology company that was later acquired by Thermo Fisher Scientific in 2016. From 1996 to 2000, Dr. Harmon founded and served as the Chief Executive Officer of Neomorphic, Inc., a computational biology company, until it was acquired by Affymetrix, Inc. Dr. Harmon received a B.A. and Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

On August 13, 2026, Olema Pharmaceuticals, Inc. announced the appointment of Jason O'Byrne as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company on July 28, 2026 and effective as of August 11, 2026. Mr. O'Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology and pharmaceutical organizations. He served as Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc., a biopharmaceutical company, from October 2024 to August 2026. Prior to that, Mr. O'Byrne served as Chief Financial Officer of Caribou Biosciences, Inc., a biopharmaceutical company, from 2021 to 2024. Across both organizations, he led a wide range of financial and capital markets initiatives, including Caribou's initial public offering. Previously, Mr. O'Byrne served as Vice President, and subsequently, Senior Vice President of Finance at Audentes Therapeutics, Inc., a biotechnology company, from 2019 to 2021, including through its acquisition by Astellas Pharma in 2020. Earlier in his career, Mr. O'Byrne spent 13 years at Genentech, Inc., a biotechnology company, and its parent company the Roche Group, a global healthcare company, where he held finance leadership positions of increasing responsibility, including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy. Mr. O'Byrne received a B.A.Sc. in mechanical engineering from the University of British Columbia and an M.B.A. in finance, with distinction, from New York University's Stern School of Business.

On April 27, 2026, the Board of Directors of Olema Pharmaceuticals, Inc. appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026. Dr. Raman brings over two decades of executive leadership and business development expertise in the biopharmaceutical industry to Olema. He currently serves as Chief Executive Officer of InduPro Therapeutics, a company developing protein therapeutics in oncology and immunology. Prior to this, he was President and Chief Executive Officer of Ribon Therapeutics, a biotechnology company focused on first-in-class small molecule drugs for oncology and immunology. Previously, he served as Senior Partner, Chief Business Development Officer at Flagship Pioneering. This followed nearly 14 years at Novartis where Dr. Raman held roles of increasing responsibility, most recently as Vice President, Global Head of Novartis Institutes for Biomedical Research (NIBR) Business Development and Licensing. While at NIBR, he played a key role in forging strategic collaborations in immuno-oncology and guiding acquisitions, including Advanced Accelerator Applications, Endocyte, IFM Tre, and Selexys, among others. Earlier in his career, Dr. Raman served as a Senior Scientist at Millennium Pharmaceuticals and as a postdoctoral fellow at The Scripps Research Institute. Dr. Raman has served as a member of the Board of Directors of Black Diamond Therapeutics since April 2024. He received his Ph.D. in Organic and Medicinal Chemistry from the University of Wisconsin-Madison and completed his undergraduate studies and a master's degree in Organic Chemistry at the Indian Institute of Technology, Bombay.

Dr. David C. Myles, PhD has served as our Chief Scientific Officer since March 2026. Prior to that, he served as our Chief Discovery and Non-Clinical Development Officer beginning in September 2022, and as our Chief Development Officer and Executive Vice President, Drug Discovery and Development beginning in April 2008. From 2006 to 2008, Dr. Myles co-founded and served as the Chief Operating Officer of Epiphany Biosciences, Inc., a biotechnology company. From 2001 to 2006, he served as the Executive Director of Chemistry at Kosan Biosciences, Inc., a biotechnology company. From 1998 to 2001, Dr. Myles served as the Associate Director of Medical Chemistry at Chiron Corporation, a biotechnology company that was later acquired by Novartis International AG, a biopharmaceutical company. From 1991 to 1998, he was an Assistant Professor in the Department of Chemistry and Biochemistry at University of California, Los Angeles. Dr. Myles currently serves as the Finance Chair on the board of directors of Point Blue Conservation Science and as President of Myles Business Park Owners, LLC. Dr. Myles received a B.A. in chemistry from Occidental College, and a Ph.D. in Chemistry from Yale University. He was a National Institute of Health post-doctoral fellow at Harvard University.

Dr. Naseem Zojwalla, M.D. has served as our Chief Medical Officer since January 2022. Prior to that, Dr. Zojwalla served as Vice President of Clinical Development at Turning Point Therapeutics, a biotechnology company (acquired by Bristol Myers Squibb, a biopharmaceutical company), from July 2020 to January 2022, and at Peloton Therapeutics, a biopharmaceutical company (acquired by Merck, a biopharmaceutical company), from March 2015 to March 2020. Earlier in her career, Dr. Zojwalla held roles of increasing responsibility at multiple oncology-focused companies, including Onyx Pharmaceuticals Inc., a biopharmaceutical company, ImClone Systems Inc., a biopharmaceutical company, and Eisai Medical Research, a pharmaceutical company. Dr. Zojwalla was previously an Assistant Clinical Professor of Medicine at Columbia University Medical Center. She received a B.S. from Stanford University, an M.D. from Temple University School of Medicine and completed her hematology/oncology fellowship training at Columbia University Medical Center.

Sasha Austin serves as Vice President of Finance and Controller at Olema Oncology, bringing a wealth of financial and accounting experience in the biotechnology industry and an expertise in US GAAP, IFRS, and public company reporting and compliance. Mrs. Austin joined Olema in January 2021 and has helped the company scale while leading the finance team on accounting operations, technical accounting, financial reporting, and related regulatory filings. Prior to joining Olema, she served as Controller at GigCapital Global, a SPAC, where she successfully managed the technical accounting, financial reporting, and related public company filings with the SEC for a number of investment and portfolio entities. Before that she worked at Ernst & Young in assurance practice where she led the financial statement audits of numerous companies at various stages, spanning from private to preclinical to commercial. She received a BA in Business Administration with concentration in Accounting and International Business from Seattle University in Washington. Mrs. Austin is an active CPA in California and a member of the AICPA.